Is Dementia Incidence Still Dropping? Birth Cohort Data Say Yes.
Dementia prevalence has come down nearly 3 percent per year for the last 40 years, with each successive birth cohort less likely to succumb.
Dementia prevalence has come down nearly 3 percent per year for the last 40 years, with each successive birth cohort less likely to succumb.
In the largest study of its kind, volunteers took cognitive tests on their devices and had their app usage monitored. Baseline data flagged people with MCI.
People who ate a healthy diet and carried less abdominal fat in midlife had better-working brains 20 years later, according to MRI scans.
P-tau181 and p-tau217 are AD biomarkers, but they are also found in blood and muscles of people with ALS.
A large meta-analysis turns up 16 new loci.
Expression of TREM2, ApoE, and complement proteins correlated with extensive plaque clearance in response to Aβ immunotherapy.
Behold the first high-resolution structure of the human Parkinson’s-related kinase bound to mitochondrial membranes.
Meta-analysis of six longitudinal studies finds that, among people who are amyloid-positive, tau PET signal rose faster in women.
Could predictions of a doubling of U.S. dementia cases by 2050 be overblown? A provocative new analysis suggests so, finding that the age-adjusted prevalence of dementia has dropped by two-thirds in the last 40 years as public health improved. That projects to only 25 percent more dementia in 2050, even with an aging population. Will positive health trends continue, or will rising obesity and diabetes reverse them?
As plaques vanish from the brain post-Aβ immunotherapy, what goes on with cells behind the scenes? Using spatial transcriptomics of postmortem brains from people immunized against Aβ 20 years ago, and from one person treated with lecanemab, scientists spotted microglia in the throes of clearing plaques. They pinpointed ApoE, TREM2, complement, and other signals as integral to the response.
New in last 7 days
Latest Comments